Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study
Background International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-b...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-07-01
|
| Series: | BMJ Oncology |
| Online Access: | https://bmjoncology.bmj.com/content/4/1/e000800.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115563906400256 |
|---|---|
| author | Andriana Barisic Samantha Harrison David Baldwin Sean McPhail Georgios Lyratzopoulos Matthew E Barclay Laura Downie Richard Walton Bin Zhang Mark Lawler John Butler Oliver Bucher Haiyan Wang Bjorn Møller Lorraine Shack Ryan R Woods Nathalie Saint-Jacques Nicola Creighton David S Morrison Luc te Marvelde Dyfed W Huws Catherine S Thomson Grace Musto Shane A Johnson Ruth Swann Riaz Alvi David A Cameron Christian J Finley Damien B Bennett Cheryl A Denny Ron A Dewar David W Donnelly Jeff J Dowden Norah Finn Steven Habbous S Eshwar Kumar Leon May Carol A McClure Yngvar Nilssen Sabuj Sarker Xiaoyi Tian Robert JS Thomas Tommy Hon Ting Wong Hui You Paul A Dawkins Sharon Fung Kathryn E Green Elba Gomez Navas Jihee Han David T Ransom |
| author_facet | Andriana Barisic Samantha Harrison David Baldwin Sean McPhail Georgios Lyratzopoulos Matthew E Barclay Laura Downie Richard Walton Bin Zhang Mark Lawler John Butler Oliver Bucher Haiyan Wang Bjorn Møller Lorraine Shack Ryan R Woods Nathalie Saint-Jacques Nicola Creighton David S Morrison Luc te Marvelde Dyfed W Huws Catherine S Thomson Grace Musto Shane A Johnson Ruth Swann Riaz Alvi David A Cameron Christian J Finley Damien B Bennett Cheryl A Denny Ron A Dewar David W Donnelly Jeff J Dowden Norah Finn Steven Habbous S Eshwar Kumar Leon May Carol A McClure Yngvar Nilssen Sabuj Sarker Xiaoyi Tian Robert JS Thomas Tommy Hon Ting Wong Hui You Paul A Dawkins Sharon Fung Kathryn E Green Elba Gomez Navas Jihee Han David T Ransom |
| collection | DOAJ |
| description | Background International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.Methods Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012–2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.Results There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) and radiotherapy (ranging from 32% in England to 48% in New South Wales and 50% in Newfoundland and Labrador). Across jurisdictions, chemotherapy use decreased steeply with increasing age, regardless of stage at diagnosis. For radiotherapy use, in stage 1–3 cancer three patterns were observed: (a) steep decrease with increasing age (UK jurisdictions, Saskatchewan-Manitoba); (b) a relatively flat pattern (Norway, Alberta, British Columbia, Atlantic Canada, New South Wales) and (c) increasing use with increasing age (Ontario).Time to radiotherapy initiation was longer in the UK jurisdictions than elsewhere; time to chemotherapy was longer in the UK and Canadian jurisdictions except Ontario.Discussion Use of chemotherapy and radiotherapy in patients with lung cancer varied substantially between jurisdictions during the mid-2010s within age-stage strata. Reasons for these variations are unclear. Differences in non-surgical treatment use are plausibly associated with international variation in lung cancer survival. |
| format | Article |
| id | doaj-art-944b84c33d9f492cb2b8ab0ab51cbe5d |
| institution | OA Journals |
| issn | 2752-7948 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Oncology |
| spelling | doaj-art-944b84c33d9f492cb2b8ab0ab51cbe5d2025-08-20T02:36:31ZengBMJ Publishing GroupBMJ Oncology2752-79482025-07-014110.1136/bmjonc-2025-000800Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study Andriana Barisic0Samantha Harrison1David Baldwin2Sean McPhail3Georgios Lyratzopoulos4Matthew E Barclay5Laura Downie6Richard Walton7Bin Zhang8Mark Lawler9John Butler10Oliver Bucher11Haiyan Wang12Bjorn Møller13Lorraine Shack14Ryan R Woods15Nathalie Saint-Jacques16Nicola Creighton17David S Morrison18Luc te Marvelde19Dyfed W Huws20Catherine S Thomson21Grace Musto22Shane A Johnson23Ruth Swann24Riaz Alvi25David A Cameron26Christian J Finley27Damien B Bennett28Cheryl A Denny29Ron A Dewar30David W Donnelly31Jeff J Dowden32Norah Finn33Steven Habbous34S Eshwar Kumar35Leon May36Carol A McClure37Yngvar Nilssen38Sabuj Sarker39Xiaoyi Tian40Robert JS Thomas41Tommy Hon Ting Wong42Hui You43Paul A DawkinsSharon FungKathryn E GreenElba Gomez NavasJihee HanDavid T RansomRenal Network, Cancer Care Ontario, Toronto, Ontario, CanadaPolicy and Information, Cancer Research UK, London, UK4 Respiratory Medicine, Nottingham University Hospitals, Nottingham, UKNHS England North, Leeds, UK6 Cambridge Centre for Health Services Research, University of Cambridge, Cambridge, UK1 The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, Cambridgeshire, UKThe University of Melbourne, Melbourne, Australia1 Cancer Institute NSW, St Leonards, New South Wales, Australia5 Mental Health Center of Tianjin University, Tianjin Anding Hospital, Tianjin, Chinaprofessor of digital healthspecialist registrar in emergency medicine11 Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canada1 Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA4 Cancer Registry of Norway, Oslo, NorwaySurveillance and Reporting, Cancer Research and Analytics, Cancer Care Alberta, Alberta Health Services, Calgary, Alberta, Canada7 BC Cancer, Vancouver, British Columbia, Canada8 Registry & Analytics, Nova Scotia Health Authority Cancer Care Program, Halifax, Nova Scotia, Canada1Cancer Institute NSW, Sydney, New South Wales, AustraliaInstitute of Health and Wellbeing, University of Glasgow, Glasgow, UK4 Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia23 Swansea University, Swansea, Wales, UKservice manager (cancer and adult screening)11 Department of Epidemiology and Cancer Registry, CancerCare Manitoba, Winnipeg, Manitoba, Canadasenior data and research analystCancer Research UK, London, UKSaskatchewan Cancer Agency, Saskatoon, Saskatchewan, CanadaEdinburgh Cancer Research Centre, Edinburgh, UK4 Division of Thoracic Surgery, Department of Surgery, McMaster University, Hamilton, Ontario, Canada10 Northern Ireland Cancer Registry, Queen’s University Belfast, Belfast, UK13 Public Health Scotland, Edinburgh, UK14 Nova Scotia Health Cancer Care Program, Halifax, Nova Scotia, Canada10 Northern Ireland Cancer Registry, Queen’s University Belfast, Belfast, UK15 Provincial Cancer Care Program, Eastern Health, St. John’s, Newfoundland and Labrador, Canada16 Victorian Cancer Registry, Cancer Council Victoria, Melbourne, Victoria, Australia9 Ontario Health, Cancer Care Ontario, Toronto, Ontario, Canada19 New Brunswick Cancer Network, Department of Health, Fredericton, New Brunswick, Canada17 Welsh Cancer Intelligence and Surveillance Unit, Public Health Data, Knowledge and Research Directorate, Public Health Wales, Cardiff, UK20 Prince Edward Island Cancer Registry, Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada21 Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway7 Epidemiology, Analytics and Surveillance, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada22 Cancer Advanced Analytics, Cancer Research & Analytics, Cancer Care Alberta, Alberta Health Services, Calgary, Alberta, Canada23 University of Melbourne, Melbourne, Victoria, Australia16 Victorian Cancer Registry, Cancer Council Victoria, Melbourne, Victoria, Australia12 Cancer Institute NSW, St Leonards, New South Wales, AustraliaBackground International variation in lung cancer survival may be partly explained by variation in stage-specific treatment use, but relevant comparative evidence is sparse. As part of the International Cancer Benchmarking Partnership, we examined use of chemotherapy and radiotherapy in population-based cancer registry data.Methods Linked population-based data sources were used to describe use and time to first treatment for either chemotherapy or radiotherapy in patients with lung cancer diagnosed in study periods during 2012–2017 in 16 jurisdictions of Australia, Canada, the UK and Norway.Results There was large variation in the proportions of patients with lung cancer receiving chemotherapy (ranging from 23% in Northern Ireland to 45% in Norway) and radiotherapy (ranging from 32% in England to 48% in New South Wales and 50% in Newfoundland and Labrador). Across jurisdictions, chemotherapy use decreased steeply with increasing age, regardless of stage at diagnosis. For radiotherapy use, in stage 1–3 cancer three patterns were observed: (a) steep decrease with increasing age (UK jurisdictions, Saskatchewan-Manitoba); (b) a relatively flat pattern (Norway, Alberta, British Columbia, Atlantic Canada, New South Wales) and (c) increasing use with increasing age (Ontario).Time to radiotherapy initiation was longer in the UK jurisdictions than elsewhere; time to chemotherapy was longer in the UK and Canadian jurisdictions except Ontario.Discussion Use of chemotherapy and radiotherapy in patients with lung cancer varied substantially between jurisdictions during the mid-2010s within age-stage strata. Reasons for these variations are unclear. Differences in non-surgical treatment use are plausibly associated with international variation in lung cancer survival.https://bmjoncology.bmj.com/content/4/1/e000800.full |
| spellingShingle | Andriana Barisic Samantha Harrison David Baldwin Sean McPhail Georgios Lyratzopoulos Matthew E Barclay Laura Downie Richard Walton Bin Zhang Mark Lawler John Butler Oliver Bucher Haiyan Wang Bjorn Møller Lorraine Shack Ryan R Woods Nathalie Saint-Jacques Nicola Creighton David S Morrison Luc te Marvelde Dyfed W Huws Catherine S Thomson Grace Musto Shane A Johnson Ruth Swann Riaz Alvi David A Cameron Christian J Finley Damien B Bennett Cheryl A Denny Ron A Dewar David W Donnelly Jeff J Dowden Norah Finn Steven Habbous S Eshwar Kumar Leon May Carol A McClure Yngvar Nilssen Sabuj Sarker Xiaoyi Tian Robert JS Thomas Tommy Hon Ting Wong Hui You Paul A Dawkins Sharon Fung Kathryn E Green Elba Gomez Navas Jihee Han David T Ransom Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study BMJ Oncology |
| title | Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study |
| title_full | Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study |
| title_fullStr | Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study |
| title_full_unstemmed | Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study |
| title_short | Chemotherapy and radiotherapy use in patients with lung cancer in Australia, Canada, the UK and Norway 2012–2017: an ICBP population-based study |
| title_sort | chemotherapy and radiotherapy use in patients with lung cancer in australia canada the uk and norway 2012 2017 an icbp population based study |
| url | https://bmjoncology.bmj.com/content/4/1/e000800.full |
| work_keys_str_mv | AT chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT andrianabarisic chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT samanthaharrison chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT davidbaldwin chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT seanmcphail chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT georgioslyratzopoulos chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT matthewebarclay chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT lauradownie chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT richardwalton chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT binzhang chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT marklawler chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT johnbutler chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT oliverbucher chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT haiyanwang chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT bjornmøller chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT lorraineshack chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT ryanrwoods chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT nathaliesaintjacques chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT nicolacreighton chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT davidsmorrison chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT luctemarvelde chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT dyfedwhuws chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT catherinesthomson chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT gracemusto chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT shaneajohnson chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT ruthswann chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT riazalvi chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT davidacameron chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT christianjfinley chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT damienbbennett chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT cheryladenny chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT ronadewar chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT davidwdonnelly chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT jeffjdowden chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT norahfinn chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT stevenhabbous chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT seshwarkumar chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT leonmay chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT carolamcclure chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT yngvarnilssen chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT sabujsarker chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT xiaoyitian chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT robertjsthomas chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT tommyhontingwong chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT huiyou chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT pauladawkins chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT sharonfung chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT kathrynegreen chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT elbagomeznavas chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT jiheehan chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy AT davidtransom chemotherapyandradiotherapyuseinpatientswithlungcancerinaustraliacanadatheukandnorway20122017anicbppopulationbasedstudy |